Expanded Colesevelam Administration Options With Oral Suspension Formulation for Patients With Diabetes and Hypercholesterolemia

References

• . Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8–13
   PubMed Web of Science ®Google Scholar
• . Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002;1:1
   PubMed Web of Science ®Google Scholar
• . Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating “sick fat” through improving fat function with antidiabetes therapies. Am J Cardiol. 2012;110( 9 Suppl):4B–12B
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Cleeman JI, Merz CN, ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
   PubMed Web of Science ®Google Scholar
• . Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• . Jellinger PS, Smith DA, Mehta AE, ; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18( Suppl 1):1–78
   PubMedGoogle Scholar
• . Ballantyne CM, Raichlen JS, Nicholls SJ, ; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458–2466
   PubMed Web of Science ®Google Scholar
• . Bozentowicz-Wikarek M, Kocelak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis—guidelines vs. reality. Pharmacol Rep. 2012;64(2):377–385
   PubMed Web of Science ®Google Scholar
• . Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–940
   PubMed Web of Science ®Google Scholar
• . Kotseva K, Wood D, De Backer G, ; EUROASPIRE Study Group. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17(5):530–540
   PubMedGoogle Scholar
• . Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–467
   PubMed Web of Science ®Google Scholar
• . Robinson JG, Ballantyne CM, Hsueh W, . Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011;5(6):474–482
   PubMed Web of Science ®Google Scholar
• . Yan AT, Yan RT, Tan M, ; Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119(8):676–683
   PubMed Web of Science ®Google Scholar
• . Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):e001800
   Web of Science ®Google Scholar
• . Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781–1790
   PubMed Web of Science ®Google Scholar
• . Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–572
   PubMed Web of Science ®Google Scholar
• . de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ; Dutch ExPRESS Investigator Group. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol. 2002;90(2):181–184
   PubMed Web of Science ®Google Scholar
• . Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17(5–6):459–465
   PubMed Web of Science ®Google Scholar
• . Kashani A, Phillips CO, Foody JM, . Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–2797
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Cleeman JI, Daniels SR, . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published correction appears in Circulation. 2005;112(17):e298]. Circulation. 2005;112(17):2735–2752
   PubMed Web of Science ®Google Scholar
• . Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32( Suppl 2):S237–S245
   PubMed Web of Science ®Google Scholar
• . Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother. 2003;4(5):779–790
   PubMed Web of Science ®Google Scholar
• . Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975–1983
   PubMedGoogle Scholar
• . Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531–1540
   PubMedGoogle Scholar
• . Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479–1484
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Abrahamson MJ, Barzilay JI, . American Association of Clinical Endocrinologists' Comprehensive Diabetes Management
   Google Scholar
• . WelChol Tablets [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2014
   Google Scholar
• . Insull W Jr, Toth P, Mullican W, . Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001;76(10):971–982
   PubMed Web of Science ®Google Scholar
• . Nwose OM, Jones MR. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2013;6:75–79
   PubMedGoogle Scholar
• . Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010;10(5):305–314
   PubMed Web of Science ®Google Scholar
• . Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158(2):407–416
   PubMed Web of Science ®Google Scholar
• . Knapp HH, Schrott H, Ma P, . Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110(5):352–360
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Toth P, Weiss S, . Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001;24(6):467–474
   PubMed Web of Science ®Google Scholar
• . McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin. 2005;21(9):1403–1412
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Rooney M, Pollock EM, Drucker JL, Choy Y. The effect of colesevelam and niacin on low-density lipoprotein cholesterol and plasma glucose [abstract]. Circulation. 2012;126( 21 Suppl):Abstract A11700
   Web of Science ®Google Scholar
• . Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22(11):2191–2200
   PubMed Web of Science ®Google Scholar
• . Stein EA, Marais AD, Szamosi T, . Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156(2):231–236, e231–233
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Dillon MA, Gordon B, . Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159(16):1893–1900
   PubMed Web of Science ®Google Scholar
• . Bays H, Jones PH. Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag. 2007;3(5):733–742
   PubMedGoogle Scholar
• . Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29(1):74–83
   PubMed Web of Science ®Google Scholar
• . Rosen J, Soni S, Hume L. Comparison of the in vitro bile acid binding of two colesevelam formulations. Presented at the 46th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; December 4–8, 2011; New Orleans, LA. http://www.softconference.com/ashp/sessionDetail.asp?SID=286111
   Google Scholar
• . Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159(22):2647–2658
   PubMed Web of Science ®Google Scholar
• . Hanus M, Zhorov E. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J Pharm Sci. 2006;95(12):2751–2759
   PubMed Web of Science ®Google Scholar
• . Kos R, White JL, Hem SL, Borin MT. Effect of competing anions on binding of bile salts by cholestyramine. Pharm Res. 1991;8(2):238–241
   PubMed Web of Science ®Google Scholar
• . Bilicki CV, White JL, Hem SL, Borin MT. Effect of anions on adsorption of bile salts by colestipol hydrochloride. Pharm Res. 1989;6(9):794–797
   PubMed Web of Science ®Google Scholar
• . Patel N, Kelley R, Jones M, Hume L, Rosen J. Preparation of colesevelam HCl powder for suspension in several beverages. Presented at the 46th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; December 4–8, 2011; New Orleans, LA. http://www.softconference.com/ashp/sessionDetail.asp?SID=286111; Abstract 5–240
   Google Scholar
• . Bays HE, Maki KC, Schmitz K. Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability. Endocr Pract. 2011;17(2):218–225
   PubMed Web of Science ®Google Scholar
• . Keech A, Simes RJ, Barter P, ; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861
   PubMed Web of Science ®Google Scholar
• . Boden WE, Probstfield JL, Anderson T, ; AIM HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267
   PubMed Web of Science ®Google Scholar
• . Cannon CP, Giugliano RP, Blazing MA, ; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826–832
   PubMed Web of Science ®Google Scholar
• . Shi L, Ye X, Lu M, . Clinical and economic benefits associated with the achievement of both HbAlc and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care. 2013;36(10):3297–3304
   PubMed Web of Science ®Google Scholar
• . QUESTRAN [package insert]. Spring Valley, NY: PAR Pharmaceutical, Inc.; 2006
   Google Scholar